Trump’s Quiet Pharma Deals Threaten Big Medicare Savings

When the Trump administration first touted its "most‑favored‑nation" (MFN) pricing plan, the headline was simple: tie Medicare drug payments to the cheapest prices paid by 19 wealthy allies, and save the nation billions. The math looked tidy, the narrative was compelling, and the promised $26 billion in savings over several years was repeated in every briefing.

But a closer look at the paperwork—some of which only a handful of industry insiders have seen—shows a different story. The White House has been negotiating private rebates with more than two dozen pharmaceutical firms, and those secret arrangements could gnaw away at the expected savings by as much as 80 percent.

The MFN idea, in theory, is straightforward. If a drug costs less in France or Japan, Medicare should pay no more than that low price. To operationalize it, the administration rolled out two pilot programs: GLOBE for Medicare Part B (the hospital‑administered drugs) and GUARD for Part D (the retail pharmacy side). Both pilots would require manufacturers to hand over extra rebates whenever their U.S. list price topped the lowest price found in the reference nations.

What the public hasn’t heard is that, instead of relying solely on transparent international price data, the administration has been striking side‑door deals with the manufacturers themselves. Those agreements, according to a newly released analysis, allow companies to keep higher list prices in exchange for confidential, lump‑sum rebates that are not tied to the MFN benchmark.

In practice, that means the rebate could be far smaller than the gap between the U.S. price and the international low. If a drug’s U.S. price is $200 per dose, and the cheapest foreign price is $120, the MFN rule would demand a $80 discount. The secret deal, however, might only give a $10 or $15 rebate—just enough to keep the company happy while leaving Medicare paying the lion’s share of the price.

Why the secrecy? Officials argue that the private negotiations give the government leverage, preventing companies from walking away from the program altogether. Critics, though, say the lack of transparency defeats the whole purpose of MFN pricing, which was meant to be a clear, rule‑based approach that patients and policymakers could track.

Even more concerning is the potential ripple effect on future drug‑price reforms. If the MFN pilots turn out to be less effective than advertised, lawmakers may lose faith in using international price references as a policy tool, pushing them toward other, possibly more cumbersome, mechanisms.

For patients, the stakes are personal. The promise of lower out‑of‑pocket costs was a key selling point of the plan, especially for those on costly specialty therapies. A reduction in projected savings means higher premiums, higher co‑pays, and ultimately, tougher choices at the pharmacy counter.

As the administration prepares to release the final rulebooks for GLOBE and GUARD later this year, stakeholders are urging greater disclosure. Advocacy groups want the rebate amounts and the list of participating companies made public, while industry watchers warn that excessive transparency could scare away the very firms needed to keep the program viable.

One thing is clear: the road to curbing soaring prescription‑drug costs is messier than the glossy slides suggest. Whether the MFN pilot will live up to its headline promise—or become a footnote in the ongoing debate over drug pricing—remains to be seen.